Abbott Laboratories $(ABT)$ shares tumbled 5.12% in pre-market trading on Thursday, despite the company reporting second-quarter results that slightly exceeded analyst expectations. The healthcare giant posted adjusted earnings per share of $1.26, marginally above the $1.25 estimate, and revenue of $11.1 billion, surpassing the projected $11.07 billion.
However, investors appear to be focusing on Abbott's forward guidance and expansion plans. For the third quarter, the company expects adjusted earnings per share in the range of $1.28 to $1.32, while for the full year 2025, it projects adjusted EPS between $5.10 and $5.20. This outlook, while in line with or slightly above current estimates, may be viewed as conservative by some market participants.
Adding to the mix, Abbott announced plans to build a new manufacturing facility in the U.S. state of Georgia by 2028. While this move signals long-term growth intentions, it could potentially impact the company's expenses in the coming years. Furthermore, Abbott provided an outlook for fiscal year 2025 organic sales growth, excluding COVID-19 testing related sales, to be in the range of 7.5% to 8.0%, which may not have met the market's more optimistic expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.